CompletedNCT04192370
Cannabidiol for Craving During Buprenorphine Treatment
About this title
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
Read the official source — NCT04192370Medication studyAges 18–75United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 75 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: August 3, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 8
- Sponsor
- Brigham and Women's Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT04192370
- Official title
Show the full official title
A Single-arm, Open-label Feasibility Pilot of Cannabidiol as an Adjunct to Sublingual Buprenorphine on Cue-induced Cravings Among Individuals With Opioid Use Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Brigham and Women's Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Cannabidiol 600mg.
Who was this study for?
Listed age limits: 18 years to 75 years.
